ClinicalTrials.gg
RecruitingNCT06081244ADAPT-TN-IIIUpdated Aug 3, 2026

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

A Phase 3 interventional study of Sacituzumab govitecan and Pembrolizumab in Triple Negative Breast Cancer, sponsored by Women's Cancer Study Group GmbH. Recruiting at 43 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Women's Cancer Study Group GmbH · Phase 3, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms — 17 open to participants now, 27 under way, 4 of them phase 3. pembrolizumab · Triple Negative Breast Neoplasms.

Planned enrollment
10th of 49
348 · median 52
Started
2024
with 7 others
Phase 3
7 of 49
3 open now
Primary completion
2029-09
later than 20 of 26 live
Registered
36th of 49
by date

Among the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, this one is the 10th largest by planned enrollment, is one of 8 that started in 2024, is one of 7 in phase 3, reaches primary completion later than 20 of the 26 other live ones, and was the 36th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

17 of the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

TNBC is known for poor prognosis, aggressive patterns of disease, and significant molecular heterogeneity. (Neo)adjuvant chemotherapy (NACT) is standard of care in all node-positive and in node-negative patients with a tumour size >5 mm according to current National Comprehensive Cancer Network (NCCN) guidelines. However, TNBC patients with lower stage disease do clearly have a better prognosis compared to more advanced stages. Patients with stage I-II node-negative disease have 3-5 year iDFS rates of 80-90% (with majority of relapses within the first three years) as shown in several trials.Although survival results appear much better in the lower vs. higher stages, there is a high clinical need in this most common group of TNBC patients in Western Europe and USA.

Read the detailed description

About 15% of breast cancers lack both, expression of ER and PR receptors, and amplification/over-expression of HER2 receptors, and are thus described as triple negative breast cancer (TNBC). TNBC is known for poor prognosis, aggressive patterns of disease, and significant molecular heterogeneity. (Neo)adjuvant chemotherapy (NACT) is standard of care in all node-positive and in node-negative patients with a tumour size >5 mm according to current National Comprehensive Cancer Network (NCCN) guidelines. However, TNBC patients with lower stage disease do clearly have a better prognosis compared to more advanced stages. Patients with stage I-II node-negative disease have 3-5 year iDFS rates of 80-90% (with majority of relapses within the first three years) as shown in several trials. Our own results from the PlanB- and ADAPT-trials, and pooled analysis with SUCCESS C-trials show 3-year iDFS of 86-90% in node-negative TNBC with a tumour size \< 3 cm. Although survival results appear much better in the lower vs. higher stages, there is a high clinical need in this most common group of TNBC patients in Western Europe and USA.

In the neoadjuvant setting, it has been shown that the prognosis of patients with TNBC is strongly dependent on their response to NACT: Patients achieving pathological complete response (pCR), or a near pCR (an excellent response after NACT (residual cancer burden (RCB) score 0-1), in some studies do have an excellent prognosis that is not significantly different from that observed in other breast cancer subtypes. However, patients with a less responsive disease (i.e., with RCB Score 2-3) suffer from a significantly worse prognosis compared to non-TNBC.

Chemotherapy in TNBC The optimal chemotherapy regimen for patients with TNBC remains to be identified. Standard anthracycline-taxane (A/T)-based NACT combinations render pCR rates between 25-50%. However, the survival impact of anthracyclines remains controversial due to conflicting results of different randomized trials. Adding carboplatin (carbo) to A/T-containing poly-NACT or use of dose-intensified poly-NACT significantly increases pCR-rates up to 49-60% in mostly stage II-III disease with conflicting survival results and higher toxicity. Hence, use of pragmatic taxane-carboplatin anthracycline-free combinations appears as an effective treatment option in TNBC instead of further treatment escalation. This probably is independent of the germline BRCA (gBRCA) status, due to its general chemo-predictive effect. Unfortunately, no prospective phase-III-data are available so far. However, indirect comparison between trials renders similar pCR rates in taxane-carboplatin based vs. A/T+/-carbo-based regimens in early TNBC.

In the ADAPT-TN neoadjuvant trial, the taxane-carbo arm (12-week nab-paclitaxel (nab-pac)+carbo) was well tolerable (only 10% SAE-rate), highly effective (pCR, ypT0/is/ypN0, of 46%) and superior to the gemcitabine (gem)-arm (nab-pac+gem, pCR of 29%). In this study, omission of further chemotherapy was allowed in patients with pCR after 12 weeks of therapy and was not associated with decreased survival after 3 years [5] and longer follow up.

Although a standard chemotherapy as well as optimal therapy duration are still to be defined, several studies are showing a comparable efficacy for longer vs. shorter adjuvant treatments in TNBC [3], as well as a similar efficacy regarding pCR in HR-negative (in contrast to HR-positive) early breast cancer (eBC) [26]. Moreover 6 vs. 4 cycles of the same chemotherapy (AC or pac weekly) yielded a similar survival outcome in eBC despite of HR-status. No such comparison regarding treatment duration is available for modern antibody-drug conjugates like sacituzumab govitecan (SG).

Therefore, an examination of shorter (12 weeks vs. 18 weeks) regimen as neoadjuvant treatment appears to be a very promising strategy at least in patients with lower risk disease or in elderly patients, who do not qualify for polychemotherapy treatments.

In the Keynote-522 trial combination of carboplatin/taxane-anthracycline NACT with the anti-PD1-antibody pembrolizumab (PEM) has been shown to be associated with a significantly higher pCR and clinically meaningful better EFS and a trend to better OS. Noteworthy only patients with more advanced stages IIa-III TNBC were included into the Keynote-522 trial. Although this effect was independent of clinically assessed nodal status, there is still some uncertainty on the optimal treatment in patients with clinical stage I.

In the metastatic setting, SG as a Trop-2-antibody-drug-conjugate has been shown to be highly efficacious in severely pre-treated patients (all with A/T pre-treated tumours, most of them carboplatin and 1/3 also anti-PD1 pre-treated) compared to chemotherapy of investigator´s choice. Treatment with SG was associated with significant longer median PFS (5.5 vs. 1.7 months) and longer median OS (12.1 vs. 6.7 months). Objective response was dramatically higher in the SG group vs. treatment by physician´s choice group (34.9 vs. 4.7%), in particular in the 2nd-3rd-line therapy (40% vs. 4%). Moreover, Tropics-02 trial has shown higher efficacy of SG vs. chemotherapy of investigator´s choice in patients with HR-positive/HER2-negative metastatic breast cancer.

In the neoadjuvant setting, recently presented results from the NeoSTAR trial show a promising pCR-rate of 30% and RCB 0-1-rate of 36% in TNBC patients with mostly stage II-III-disease (about 80%) after only 4 cycles of SG.

The following clinical questions are of highest medical need

  1. Can 12-18 weeks neoadjuvant treatment with SG alone or in combination with PEM be associated with comparable pCR-rates (but more favourable safety profile) as shown for polychemotherapy in TNBC patients at lower relapse risk in historical controls?
  2. Can SG-based therapy, as the most promising agent in patients with chemo-resistant disease, be associated with a such better prognosis (measured by 3-year-iDFS) compared to historical controls, which would make a randomized phase III-trial obsolete?
03

Conditions studied

  • Triple Negative Breast Cancer

Keywords

  • TNBC
  • Early breast cancer
  • Sacituzumab govitecan
  • pembrolizumab
  • chemotherapy
  • low recurrence risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ER + PR negative or low positive (≤10% positive cells in IHC), and negative (i.e., IHC 0 - 1+ or IHC 2+ with FISH negative) breast cancer
  2. All patients, independent from gender
  3. ≥18 years at diagnosis
  4. confirmed unilateral, primary invasive carcinoma of the breast Note: bilateral, multicentric, or multifocal carcinoma may be included, if there is a clear target lesion, that is subject to treatment decisions and solely evaluated and documented for study purposes.
  5. Clinical stage I: cT1a-c, cN0 (clinical stage II only, if patient does not qualify for polychemotherapy+PEM, e.g., elderly population, per investigator´s decision)
  6. No clinical evidence for distant (M0)
  7. Tumour block available for central pathology review
  8. Performance Status ≤ 1 or KI ≥ 80%
  9. Negative pregnancy test (urine or serum) within 7 days prior to registration in premenopausal patients
  10. Written prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements
  11. The patient must be willing and able to comply with the requirements and restrictions in this protocol and accessible for treatment and follow-up
  12. Laboratory requirements:

    • Leucocytes ≥3.5 109/L,
    • Neutrophils > 1.5 109/L,
    • ≥100 109/L,
    • ≥10 g/dL,
    • AP \< 5.0 ,
    • ≤2.5 x ULN,
    • ALT ≤2.5 x ULN,
    • Total ≤1 x ULN,
    • Creatinine ≤1.5 × ULN OR clearance ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN
  13. Clinical assessments:

    • within normal limits of each institution, measured by echocardiography and normal (within 42 days prior to treatment)
  14. The following age-specific requirements apply:

    • Women aged \<50 years will be considered if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site.
    • Women aged ≥ 50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments.
  15. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the methods outlined for women of if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to randomization/study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
  16. Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception, presented in Table 1 (see Section 4.4.2), from the time of screening and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of IMP. Complete heterosexual abstinence for the duration of the study and drug is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic, or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable.
  17. Female patients must not donate, or retrieve for their own use, ova from the time of randomisation and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrolment in this study.
  18. A male participant must agree to use a contraception as detailed in Appendix C of this protocol during the treatment period and for at least 7 months after the last dose of study treatment and refrain from donating sperm during this period.

Exclusion criteria

Exclusion Criteria:

  1. Known reaction to the compounds or incorporated substances of the IMPs
  2. Prior with a disease-free survival of \< 5 years, except curatively treated basalioma of the skin or pTis of the cervix uteri
  3. Any history of invasive breast cancer
  4. Previous or concurrent treatment with cytotoxic agents for any non-oncological reason unless clarified with sponsor
  5. Concurrent treatment with other experimental drugs
  6. Participation in another interventional clinical trial with or without any not marketed drug within 30 days prior to study entry
  7. Concurrent pregnancy; patients of or potentially childbearing partners of male patients must implement a highly effective (less than 1% failure rate) non-hormonal measures during the study treatment
  8. Breast feeding woman
  9. Reasons indicating risk of poor compliance
  10. Patients not able to consent
  11. Known polyneuropathy ≥ grade 2
  12. Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including recovery from major surgery, disease, known psychiatric/substance abuse disorders, acute cystitis, ischuria, and chronic kidney disease
  13. Uncontrolled infection requiring i.v. antibiotics, antivirals, or antifungals
  14. History of pneumonitis
  15. Active primary immunodeficiency, known (HIV) infection, or active or C infection. Patients positive for (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Patients should be tested for HIV prior to randomisation if required by local regulations or ethics committee (EC).
  16. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.

    • Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.
    • Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require a HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease.
  17. Patients who test positive for HIV antibody.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
348 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant treatment: 12 weeks (4 cycles) SG i.v.

    * Cohort 1a: In case of (near) cCR: end of treatment, followed by surgery * Cohort 1b: In case of cPR after 12 weeks: further 6 weeks (2 cycles) SG i.v., followed by surgery (use of core biopsy is allowed per investigator´s decision, if further NACT is planned) pCR dependent post-neoadjuvant treatment * In case of pCR: no further systemic treatment * In case of non-pCR: chemotherapy according to investigators decision, e.g., AC/EC q3w x 4, PAC/Carbo q1w x 12

    Drug: Sacituzumab govitecan

  • Experimental
    Neoadjuvant treatment: 12 weeks (4 cycles) SG+PEM i.v.

    * Cohort 2a: In case of (near) cCR: end of treatment, followed by surgery * Cohort 2b: In case of cPR after 12 weeks: 6 weeks (2 cycles) SG+PEM i.v., followed by surgery (use of core biopsy is allowed per investigator´s decision, if further NACT is planned) pCR dependent post-neoadjuvant treatment * In case of pCR: no further systemic treatment * In case of non-pCR: chemotherapy according to investigators decision, e.g., AC/EC q3w x 4, PAC/Carbo q1w x 12

    Drug: Sacituzumab govitecan · Drug: Pembrolizumab

Interventions

  • 10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle

    Also known as: Trodelvy

  • 200 mg every 3 weeks (q3w)

    Also known as: Keytruda

06

What researchers measure

Primary outcomes

  1. pathological complete remission (pCR)

    no invasive tumour in breast and lymph nodes (ypT0/is and ypN0)

    Time frame: at surgery

  2. invasive disease-free survival rate (iDFS),

    time from date of first diagnosis to any invasive breast cancer event, death or secondary malignancy according to STEEP 2.0 criteria

    Time frame: after 3 years

Secondary outcomes

  1. Overall survival (OS)

    time from first diagnosis to death

    Time frame: 6 years

  2. distant disease-free survival (dDFS)

    distant disease-free survival

    Time frame: after 3 years

  3. distant disease-free interval (dDFI)

    distant disease-free interval

    Time frame: after 3 years

  4. recurrence-free survival (RFS)

    recurrence-free survival

    Time frame: after 3 years

  5. local recurrence-free survival (LRFS)

    local recurrence-free survival

    Time frame: after 3 years

  6. Breast cancer free interval (BCFI)

    Breast cancer free interval

    Time frame: after 3 years

  7. Health-related Quality of Life: Quality of Life Questionnaire C30

    change in QLQ-C30-Score; min 0 - max 100 points; the higher the better quality of life

    Time frame: Baseline to end of cycle 2 (each cycle is 21 days)

  8. Health-related Quality of Life: Quality of Life Questionnaire BR45

    change in BR45-Score; min 0 - max 100 points; the higher points on functional scale the better the function; the higher points on symptom scale the higher the symptomatology.

    Time frame: Baseline to end of cycle 2 (each cycle is 21 days)

  9. Health-related Quality of Life: Quality of Life Questionnaire C30

    change in QLQ-C30-Score; min 0 - max 100 points; the higher the better quality of life

    Time frame: Baseline to end of cycle 4 (each cycle is 21 days)

  10. Health-related Quality of Life: Quality of Life Questionnaire BR45

    change in BR45-Score; min 0 - max 100 points; the higher points on functional scale the better the function; the higher points on symptom scale the higher the symptomatology.

    Time frame: Baseline to end of cycle 4 (each cycle is 21 days)

  11. Health-related QoL: EORTC QLQ-C30

    change in QLQ-C30-Score; min 0 - max 100 points; the higher the better quality of life

    Time frame: Baseline to end of cycle 6 (each cycle is 21 days)

  12. Health-related Quality of Life: Quality of Life Questionnaire BR45

    change in BR45-Score; min 0 - max 100 points; the higher points on functional scale the better the function; the higher points on symptom scale the higher the symptomatology.

    Time frame: Baseline to end of cycle 6 (each cycle is 21 days)

  13. Health-related QoL: EORTC QLQ-C30

    change in QLQ-C30-Score; min 0 - max 100 points; the higher the better quality of life

    Time frame: Baseline to timepoint before surgery

  14. Health-related QoL: EORTC QLQ-BR45

    change in QLQ-BR45-Score

    Time frame: Baseline to timepoint before surgery

  15. Health-related Quality of Life: Quality of Life Questionnaire C30

    change in QLQ-C30-Score; min 0 - max 100 points; the higher the better quality of life

    Time frame: Baseline to timepoint 1 year after surgery

  16. Health-related Quality of Life: Quality of Life Questionnaire BR45

    change in BR45-Score; min 0 - max 100 points; the higher points on functional scale the better the function; the higher points on symptom scale the higher the symptomatology.

    Time frame: Baseline to timepoint 1 year after surgery

Other outcomes

  1. Other pCR-definitions

    ypT0/is, any ypN * ypT0, ypN0 * near pCR (ypT1a/is, any ypN)

    Time frame: at time of surgery

  2. stromal tumour infiltrating lymphocytes (sTIL)

    percentage of sTIL

    Time frame: at baseline and after 3 weeks of therapy

07

Study locations

38 of 43 sites recruiting
  • Stadtklinik Baden-Baden / Brustzentrum
    Baden-Baden, Baden-Wurttemberg 76532, Germany
    Recruiting
    • Martina Koch · Contact
    • Katharina Maier · Contact
    • Antje Hahn, Dr. med. · Principal investigator
    • Uwe Cramer · Sub investigator
  • Kliniken Böblingen
    Böblingen, Baden-Wurttemberg 71032, Germany
    Recruiting
    • Simone Haas · Contact
    • Marion Ruhs · Contact
    • Grischa Wachsmann, Dr. · Principal investigator
    • Charlott-Amelie Schleich, Dr. · Sub investigator
  • Praxis für interdisziplinäre Onkologie & Hämatologie
    Freiburg im Breisgau, Baden-Wurttemberg 79110, Germany
    Recruiting
    • Sabine Souchon · Contact
    • Linda Hinrichs · Contact
    • Matthias Zaiss, Dr. · Principal investigator
    • Tilman Kirste, Dr. · Sub investigator
  • SLK Kliniken Heilbronn, Frauenklinik
    Heilbronn, Baden-Wurttemberg 74078, Germany
    Recruiting
    • Cosima Beiermeister · Contact
    • Ceylan Steinacker · Contact
    • Nikolaus De Gregorio, Prof. Dr. · Principal investigator
    • Beatrix Janke · Sub investigator
  • Universitätsklinikum Tübingen
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
    • Yvonne Löffler · Contact
    • Bettina Walter-Thorwart · Contact
    • Andreas Hartkopf, Prof. Dr. · Principal investigator
    • Tobias Engler, Dr. · Sub investigator
  • Universitätsklinikum Ulm
    Ulm, Baden-Wurttemberg 89075, Germany
    Recruiting
    • Evelyn Ziel · Contact
    • Heike Fabing · Contact
    • Brigitte Rack, Prof. Dr. · Sub investigator
    • Angelina Fink, Dr. · Principal investigator
  • GRN Klinik Weinheim
    Weinheim, Baden-Württembergs 69469, Germany
    Recruiting
    • Snjezana Stein · Contact
    • Antje Beyer · Contact
    • Lelia Bauer, Dr. med. · Principal investigator
    • Bettina Müller, Dr. med. · Sub investigator
  • Hämatologie-Onkologie im Zentrum MVZ GmbH
    Augsburg, Bavaria 86150, Germany
    Recruiting
    • Luminita Urban · Contact
    • Nina Wittmann · Contact
    • Bernhard Heinrich, Dr. med. · Principal investigator
    • Markus Bangerter, Prof. Dr. · Sub investigator
  • Universitätsklinikum Augsburg A.ö.R.
    Augsburg, Bavaria 86156, Germany
    Recruiting
    • Kwi Ja Kim · Contact
    • Sonja Dannecker · Contact
    • Nina Ditsch, Prof. Dr. · Principal investigator
    • Melitta Köpke, Dr. · Sub investigator
  • Rotkreuzklinikum München
    München, Bavaria 80637, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • DBZ Onkologie GmbH
    Berlin, Brandenburg 12623, Germany
    Recruiting
    • Angret Wetzel · Contact
    • Katja Gauger · Contact
    • Antje Müller, Dr. med. · Principal investigator
    • Evelyn Hufenbach, Dr. med. · Sub investigator
  • Klinikum Ernst von Bergmann gGmbH
    Potsdam, Brandenburg 14467, Germany
    Recruiting
    • Bettina Schinke · Contact
    • Ina Lehmann · Contact
    • Björn Beurer, Dr. · Principal investigator
    • Dorothea Fischer, Prof. · Sub investigator
  • Mammazentrum Hamburg am Krankenhaus Jerusalem
    Hamburg, Free and Hanseatic City of Hamburg 20357, Germany
    Recruiting
    • Silke Kassner · Contact
    • Kathleen Bever · Contact
    • Christian Schem, Prof. Dr. · Principal investigator
    • Anne-Sopie Adam, Dr. · Sub investigator
  • Hämatologisch/Onkologische Schwerpunktpraxis Bremen
    Bremen, Free Hanseatic City of Bremen 28209, Germany
    Recruiting
    • Heike Munzinger · Contact
    • Ralf Meyer, Dr. med. · Principal investigator
    • Carsten Schreiber, Dr. med. · Sub investigator
  • Klinikum Bremerhaven Reinkenheide gGmbH
    Bremerhaven, Free Hanseatic City of Bremen 27574, Germany
    Suspended

    Not enrolling at this site — choose another above.

  • AGAPLESION Markus Krankenhaus
    Frankfurt am Main, Hesse 60431, Germany
    Recruiting
    • Madeleine Modrow · Contact
    • Aynur Koccu-Yüzlek · Contact
    • Marc Thill, Prof. Dr. · Principal investigator
    • Christiane Brandi, Dr. · Sub investigator
  • MVZ II der Niels Stensen Kliniken
    Georgsmarienhütte, Lower Saxony 49124, Germany
    Recruiting
    • Nicole Weimer · Contact
    • Miriam Kischkel · Contact
    • Jost Wamhoff, Dr. · Principal investigator
    • Petra Hoffknecht, Dr. med. · Sub investigator
  • Gynäkologische Gemeinschaftspraxis-Ärztehaus am Bahnhofsplatz
    Hildesheim, Lower Saxony 31134, Germany
    Recruiting
    • Andrea Meyer-Kühn · Contact
    • Christoph Busch · Contact
    • Christoph Uleer, Dr. · Principal investigator
    • Jasmin Pourfard, Dr. · Sub investigator
  • Klinikum der Universität München
    München, München 80336, Germany
    Recruiting
    • Beate Rank · Contact
    • Nadine Jäger · Contact
    • Nadia Harbeck, Prof. Dr. · Principal investigator
    • Rachel Würstlein, Prof. Dr. · Sub investigator
  • Ev. Krankenhaus Berlin-Spandau
    Berlin, North Rhine-Westphalia 13589, Germany
    Recruiting
    • Sophia Yap · Contact
    • Ute Moritz · Contact
    • Silke Polata, Dr. · Principal investigator
    • Sonja Cardenas, Dr. · Sub investigator
  • Onkologische Schwerpunktpraxis Bielefeld
    Bielefeld, North Rhine-Westphalia 33604, Germany
    Recruiting
    • Birgit Reunig- Bruns · Contact
    • Stefanie Horstmann · Contact
    • Siemke Steinke, Dr. med. · Principal investigator
    • Paul Düwel, Dr. med. · Sub investigator
  • St. Elisabeth-Krankenhaus Köln-Hohenlind
    Cologne, North Rhine-Westphalia 50935, Germany
    Recruiting
    • Sigrun Wolfsturm · Contact
    • Britta Wenzel · Contact
    • Claudia Schumacher, Dr. · Principal investigator
    • Anne-Katrin Oligmüller, Dr. · Sub investigator
  • Kliniken der Stadt Köln, Krankenhaus Holweide
    Cologne, North Rhine-Westphalia 51067, Germany
    Recruiting
    • Fatima Kourisna · Contact
    • Alexandra Karachristos · Contact
    • Myriam Vincent · Principal investigator
    • Simone Drenkelfort, Dr. med · Sub investigator
  • Gyn. Oncology Clinic Research UG
    Düsseldorf, North Rhine-Westphalia 40235, Germany
    Recruiting
    • Juliane Lubitz · Contact
    • Athina Kostara, Dr. med. · Principal investigator
  • MVZ Medical Center Düsseldorf - GynOnco
    Düsseldorf, North Rhine-Westphalia 40235, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • St. - Antonius - Hospital
    Eschweiler, North Rhine-Westphalia 52249, Germany
    Recruiting
    • Katja Ohlen · Contact
    • Franziska Wilhelm · Contact
    • Peter Staib, PD Dr.med. · Principal investigator
    • Matthias Humberg · Sub investigator
  • Universitätsklinikum Essen
    Essen, North Rhine-Westphalia 45130, Germany
    Recruiting
    • Clarissa Judith Piotrowsky · Contact
    • Svenja Krüger · Contact
    • Ann-Kathrin Bittner, Dr. · Principal investigator
    • Oliver Hoffmann, PD Dr. · Sub investigator
  • Kliniken Essen-Mitte
    Essen, North Rhine-Westphalia 45136, Germany
    Recruiting
    • Sandra Riefers · Contact
    • Tanja Voelker · Contact
    • Jennifer Spönlein, Dr. med. · Principal investigator
    • Sherko Kümmel, Prof. Dr. · Sub investigator
  • ev. Klinikum Gelsenkirchen - Klinik für Senelogie
    Gelsenkirchen, North Rhine-Westphalia 45879, Germany
    Recruiting
    • Simone Herholz · Contact
    • Nobubele Mlangeni · Contact
    • Hans Holger Fischer · Principal investigator
    • Abdallah Abdallah, Dr. med. · Sub investigator
  • St. Barbara Klinik Hamm GmbH
    Hamm, North Rhine-Westphalia 59073, Germany
    Recruiting
    • Anke Föert · Contact
    • Gabriele Kerkmann · Contact
    • Claudia Strunk, Dr. · Principal investigator
    • Wlodzimierz Badur, Dr. · Sub investigator
  • Klinikum Leverkusen gGmbH
    Leverkusen, North Rhine-Westphalia 51375, Germany
    Recruiting
    • Kira Radojewski · Contact
    • Katja Pöggel-Krämer · Contact
    • Andrea Heider, Dr. · Principal investigator
    • Dagmar Sent · Sub investigator
  • Ev. Krankenhaus Bethesda Brustzentrum Niederrhein
    Mönchengladbach, North Rhine-Westphalia 41061, Germany
    Recruiting
    • Carolin Sydlik · Contact
    • Mona Schwark · Contact
    • Katja Krauß, Dr. · Sub investigator
    • Raquel von Schumann · Principal investigator
  • MVZ MediaVita, St. Franziskus-Hospital Münster
    Münster, North Rhine-Westphalia 48145, Germany
    Recruiting
    • Sarah Damerau · Contact
    • Maria Walter · Contact
    • Stefanie Wiebe, Dr. med. · Principal investigator
    • Corina Neumann, Dr. med. · Sub investigator
  • MKS St.Paulus GmbH (ehem.Marienkrankenhaus)
    Schwerte, North Rhine-Westphalia 58239, Germany
    Recruiting
    • Johanna Westkämper · Contact
    • Kristin Backhaus · Contact
    • Asja Sborowski, Dr. med. · Principal investigator
    • Michael Hartmann, Dr. · Sub investigator
  • Praxisnetzwerk Hämatologie und Onkologie, Troisdorf
    Troisdorf, North Rhine-Westphalia 53840, Germany
    Recruiting
    • Petra Bois · Contact
    • Sylvia Gawor-Becker · Contact
    • Ruth Reihs · Principal investigator
    • Helmut Forstbauer · Sub investigator
  • Marien Hospital Witten
    Witten, North Rhine-Westphalia 58452, Germany
    Recruiting
    • Anika Schmidt · Contact
    • Baerbel Buchwald · Contact
    • Monika Graeser, Dr. · Principal investigator
    • Matthias Zeth · Sub investigator
  • Helios Universitätsklinikum Wuppertal Barmen
    Wuppertal, North Rhine-Westphalia 42283, Germany
    Recruiting
    • Karina Weinhardt · Contact
    • Manuela Smiljanic · Contact
    • Vesna Bjelic-Radisic, Prof. Dr. · Principal investigator
    • Oliver Schmalz, Dr. · Sub investigator
  • Klinikum Mutterhaus-Trier
    Trier, Rhineland-Palatinate 54290, Germany
    Recruiting
    • Natalja Frick · Contact
    • Eva Junk · Contact
    • Sebastian Jud, Prof. Dr. · Principal investigator
    • Marion Klieden, Dr. · Sub investigator
  • Caritasklinikum Saarbrücken
    Saarbrücken, Saarland 66113, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Johanniter GmbH Johanniter Krankenhaus Stendal
    Stendal, Sachsen-Anhalts 39576, Germany
    Recruiting
    • Beate Müller · Contact
    • Stefanie Stiller · Contact
    • Sylvia Ruth, Dr. · Principal investigator
    • Beate Koberstein, Dr. · Sub investigator
  • Klinikum Chemnitz gGmbH
    Chemnitz, Saxony 09116, Germany
    Recruiting
    • Eileen Edle von der Planitz, Dr. med. · Contact
    • Paul Gaß, PD. Dr. · Principal investigator
    • Anja Leonhardt, Dr. med. · Sub investigator
  • Universitätsklinikum Leipzig
    Leipzig, Saxony 04103, Germany
    Recruiting
    • Andrea Bendig · Contact
    • Bahriye Aktas, Prof.Dr.med. · Principal investigator
    • Susanne Briest, Dr. med. · Sub investigator
    • Dirk Forstmeyer, Dr. · Sub investigator
  • Charité Campus Mitte Universitätsklinikum Berlin
    Berlin, State of Berlin 10117, Germany
    Suspended

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2029, 59 months after the start.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 59 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Oct 13, 2023
StartActual
Oct 10, 2024
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06081244
Lead sponsor
Women's Cancer Study Group GmbH
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Oct 10, 2024
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Aug 3, 2026

Study contacts

Oleg Gluz, PD Dr.
Contact
oleg.gluz@wsg-online.com
+492161566230
Anja Braschoß
Contact
anja.braschoss@wsg-online.com
+4917682119153
Peter Schmid, Prof Dr PHD
principal investigator · Westdeutsche Studiengruppe GmbH
Nadia Harbeck, Prof Dr
principal investigator · Breast Centre, Dept. Obstetrics & Gynaecology and CCC Munich LMU University Hospital
Oleg Gluz, PD Dr
principal investigator · Breast Centre, Evang. Bethesda-Hospital, Moenchengladbach
Sherko Kuemmel, Prof Dr
principal investigator · Breast Centre, Kliniken Essen Mitte
Monika Graeser, PD Dr..
principal investigator · Breast Centre, Evang. Bethesda-Hospital, Moenchengladbach

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion